www.INTERPHEX.com

Spring 2025

Credits for IPT Spring 2025

WWW.TERRAPINN.COM/FLABS/IPT

The first yellow trumpets of daffodil heads are appearing in our fields, and there’s a fresh quality to the air that lifts the spirits and encourages innovation. This attitude is reflected in pharmatech’s unceasing push for improvement in an industry all-too-often bogged down in tradition.

WWW.TERRAPINN.COM/LLL/IPT

IPT highlights some of the most recent exciting advancements in pharmaceutical manufacturing

What are some challenges with multi-tip tooling, and how can these be overcome?

Julien Muzard at Entegris speaks to IPT about how innovations in downstream cell processing platforms will improve biologics therapeutics manufacturing, and the impact artificial intelligence will have on the sector

CARBOGEN AMCIS is a leading global contract development and manufacturing organisation (CDMO), trusted by pharmaceutical and biopharmaceutical companies worldwide. With over 40 years of expertise, the company offers an integrated suite of services across drug substance and drug product development, helping clients to bring life-changing therapies to market with precision and efficiency.

With a strong track record in complex chemistry, CARBOGEN AMCIS offers end-to-end drug substance solutions, from preclinical development to commercial supply.

Our expertise in drug product development encompasses a wide range of pharmaceutical services. From formulation design to commercial-scale manufacturing, we specialise in efficiently bringing your drug product to market while ensuring full compliance with regulatory standards. Our highly skilled team at our state-of-the-art facility in Saint-Beauzire, France, ensures that your drug product is manufactured with precision and meets the highest quality standards.

CARBOGEN AMCIS’ Manchester, UK, site plays a crucial role in early-phase drug development, providing high-quality starting materials and building blocks across industries, including pharmaceuticals, cosmetics, electronics and dental applications.

www.carbogen-amcis.com

One of the biggest events of its kind in Europe, mmc2025 (incorporating EMAG 2025) will bring you the very best in microscopy, imaging and cytometry from across the globe.

www.rms.org.uk/membership

Bispecific antibodies are revolutionising biotherapeutic development, offering enhanced efficacy by targeting two antigens simultaneously. However, their structural complexity presents significant purification challenges. Advances in mixed-mode chromatography and scalable purification strategies are optimising production, improving yield, purity and cost efficiency, while ensuring a seamless transition from research to commercial manufacturing

Ruizhi Wang at Abselion talks to IPT about how non-optical sensor technologies are unlocking critical process data at the bench and bioreactor

The implementation of spatial technologies advances disease research, but challenges must be overcome before spatial multi-omics becomes broadly accessible

bioeuropespring.com

The evolution of DNA sequencing – from Sanger to cutting-edge next generation approaches like Illumina, Nanopore and Single Molecule, Real-Time (PacBio) sequencing – has brought advances in speed, cost and accessibility. However, what challenges are faced in throughput scale-up, and what promise does automation hold for transforming genomics and personalised medicine?

www.samedanltd.com

The pharma industry needs a way to ensure the right therapies are getting to the right patients, in a timely and cost-effective way. How are advances in researchers’ understanding of genomics aiding not only precision medicine for rare diseases, but also for common health conditions?

While RNA molecules have demonstrated promising results as therapeutics for difficult-to-treat disease indications, their current limitations in terms of delivery mean their full potential is not being realised. How can this be overcome?

Digital tools, such as artificial intelligence, are improving pharma drug discovery

How will advancements in technology affect the pharma sector, from both commercial and R&D points of view?

James Kugler at EMD Digital/Merck speaks to IPT about how counterfeit drugs, regulatory pressures and supply chain vulnerabilities demand a greater level of transparency in pharmaceutical manufacturing. Cyber-physical trust platforms, which provide an immutable link between physical products and their digital twins, will set a new standard and revolutionise the industry

IPT talks to David Fuller at Artificial Inc about how automated labs are revolutionising the pharma R&D space by connecting disparate systems, easing the burden of manual tasks on workers, and speeding up time-to-market with tools such as artificial intelligence

IPT talks to Roya Amini-Naieni at Trilobio about robotic automation in pharma research, the different applications of soft-and hardware, and how the field is likely to develop over the next five years

A collation of the top pharma events for Spring 2025!

www.londonbiotechshow.com

www.natoli.com